Semiha ÖZKAN, Işıl FİDAN, Sevgi YÜKSEL, Turgut İMİR

Telitromisinin insan polimorf nüveli lökosit fonksiyonları üzerine etkisinin in-vitro araştırılması

Polimorf nüveli lökositler (PNL), infeksiyonlara karşı konak savunmasında önemli rol oynamaktadırlar. Bakteriyel ve fungal infeksiyonlu hastaların tedavisinde kullanılan antibiyotikler için PNL'lerin fagositoz ve hücre içi öldürme aktivitesini arttırması istenen bir özelliktir. Bu çalışmada ketolid grubu yeni bir antibiyotik olan telitromisin (HMR 3647)'in sağlıklı kişilerin PNL'leri üzerine etkisi araştırılmıştır. PNL'lerin fagositozunu ve hücre içi öldürme aktivitesini ölçmek için Candida albicans ATCC 10231 suşu kullanılmıştır. Fagositik aktivite tayininde 100 PNL içinde maya hücrelerini fagosite etmiş olan PNL'ler sayılmış, kandidasidal aktivite tayininde ise 100 PNL içinde fagosite olan maya hücrelerinden PNL'ler tarafından öldürülen maya hücreleri sayılarak % cinsinden ifade edilmiştir. Telitromisinin kontrole göre fagositoz ve hücre içi ölüm oranını arttırdığı gözlenmiştir. Sonuç olarak, telitromisinin terapötik konsantrasyonlarda sağlıklı kişilerde PNL fonksiyonlarını in-vitro olarak stimüle ettiği, bu nedenle özellikle immün sistemi baskılanmış kişilerde infeksiyonların tedavisinde etkili olabileceği düşünülmüştür.

Anahtar Kelimeler:

Nötrofiller, Fagositoz

Investigation of in vitro efficacy of telithromycin on human polymorphonuclear leucocyte functions

Polymorphonuclear leucocytes (PMNLs) have a significant role on host defense against infections. It is desired that antibiotics could also increase the phagocytosis and intracellular killing activity of PMNLs in the therapy of bacterial and fungal infections in patients. In the present study, the effects of telithromycin (HMR 3647), one of the new ketolides, on the healthy human PMNLs were investigated. The C.albicans ATCC 10231 strain was used to investigate the phagocytosis and intracellular killing activity of PMNLs. The phagocyte activity index was calculated as the percentage of ingested yeast cells per 100 PMNLs, while the candidacidal index was calculated as the percentage of dead C.albicans (stained blue) ingested by 100 PMNLs. It was observed that telithromycin enhanced intracellular killing of bacteria and phagocytosis according to control cells that contain no antimicrobial agent. As a result, it was thought that telithromycin stimulate in vitro the healthy human PMNL functions at therapeutic concentrations. So, it was considered that telithromycin may have additional efficacy in the therapy of particularly immunsupressed patients.

Keywords:

Neutrophils, Phagocytosis,

PDF

___

1. Ackermann G, Rodloff AC: Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide, J Antimicrob Chemother 2003;51(3):497- 511.
2. Baltch AL, Smith RP, Ritz WJ, Franke MA, Michelsen PB: Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila, J Antimicrob Chemother 2000; 46(1):51-5.
3. Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Aralar P, Young LS: Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment, Antimicrob Agents Chemother 2001;45(8):2210-4.
4. Bonnefoy A, Guitton M, Delachaume C, Le Priol P, Girard AM: In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models, Antimicrob Agents Chemother 2001;45(6):1688-92.
5. Edelstein PH, Edelstein MAC: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia, Antimicrob Agents Chemother 1999;43(1):90-5.
6. Gemmell CG: Antibiotics and neutrophil function-potential immunomodulating activities, J Antimicrob Chemother 1993;31 (Suppl B):S23-33.
7. Kadir T, İzettin FV, Cevikbas A, Johansson CB, Clark P: In vitro effects of claritromycin on human polymorphonuclear leukocyte functions, Chemotherapy 2000;46(3):198-203.
8. Labro MT: Intraphagocytic penetration of macrolide antibiotics, "Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds): Macrolides: Chemistry, Pharmacology and Clinical Use" kitabında s. 379-88, Arnette-Blackwell, Paris (1993).
9. Labro MT: Effect of macrolides on host natural defenses, "Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds): Macrolides: Chemistry, Pharmacology and Clinical Use" kitabında s. 389-408, Arnette-Blackwell, Paris (1993).
10. Labro MT: Intracellular bioactivity of macrolides, Clin Microbiol Infect 1996;1(Suppl 1):S24-30.
11. Labro MT: Effects of macrolides on leukocytes and inflammation, "Zinner SH, Young LS, Acar JF (eds): Expanding Indications of the New Macrolides, Azalides and Streptogramins" kitabında s. 101-16, Marcel Dekker, New York (1997).
12. Mandell GL, Coleman E: Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils, Antimicrob Agents Chemother 2001;45(6):1794-8.
13. Mandell GL, Vest TK: Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies, J Infect Dis 1972;125(5):486- 90.
14. Mathers DL, Hassman J, Tellier G: Efficacy and tolerability of oncedaily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults, Clin Ther 2004; 26(1): 48-62.
15. NCCLS (Çeviri editörü Gür D): Antibiyotik Duyarlılık Testleri için Uygulama Standartları; Onikinci Bilgi Eki, M100-S12, Bilimsel Tıp Yayınevi, Ankara (2002).
16. Parnham MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections, Curr Opin Infect Dis 2005;18(2):125-31.
17. Pascual A, Garcia I, Conejo C, Perea E: Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes, Antimicrob Agents Chemother 1993;37(2):187-91.
18. Richardson MD, Scott G, Shankland GS: Effects of cilofungin on phagocytosis and intracellular killing of Candida albicans by human neutrophils, Eur J Clin Microbiol Infect Dis 1996;11(1):22-8.
19. Root R, Isturiz R, Molavi A , Metcalf JA, Malech HL: Interactions between antibiotics and human neutrophils in the killing of staphylococci, J Clin Invest 1981;67(1):247-59.
20. Soyoğul Ü: Candida albicans'a karşı flukonazolün insan polimorf nüveli lökosit fonksiyonları üzerine in vivo etkisinin araştırılması, M.Ü. Sağlık Bilimleri Enstitüsü, Doktora Tezi, İstanbul (1994).
21. Van VB-Vanholder R, De PP, Vogelaers D, Ringoir S: Immunomodulating effects of antibiotics: literature review, Infection 1996; 24(4):275- 80.
22. Vazifeh D, Abdelghaffar H, Labro T: Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin, Antimicrob Agents Chemother 2002; 46(5):1364-74.
23. Vidya KC, Mallya PS, Rao PS: Inhibition of bacterial adhesion by subinhibitory concentrations of antibiotics, Indian J Med Microbiol 2005;23(2):102-5.